2384 La Mirada Drive
About SommetricsSommetrics, a privately funded company based in San Diego, develops products and services aimed at enhancing health and well-being by improving sleep quality. The company’s proprietary aer+ technology targets disorders related to the narrowing of the airway during sleep, such as obstructive sleep apnea and chronic snoring. Sommetrics has an FDA-cleared and CE-marked acute care product, which addresses airway narrowing commonly caused by mild to moderate sedation.
Founder: Jerry Aarestad
CEO: Richard Rose
COO: Peter Schineller
Please click here for Sommetrics job opportunities.
Tweets by Sommetrics
18 articles with Sommetrics
Sommetrics Receives FDA Breakthrough Device Designation for Its aerSleep II Product to Treat Sleep Apnea
Sommetrics , a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase but does not alter the basic requirements for market authorization. The Breakthrough Device program is intended to help patients gain mo
Sommetrics Requests Emergency Use Authorization to Introduce Its aerSleep Product for Sleep Apnea Patients at Risk of COVID-19
Sommetrics , Inc., a company providing products and services to improve sleep quality, announced it filed an application with the FDA for Emergency Use Authorization to introduce its aerSleep® II product to treat obstructive sleep apnea in people at risk of COVID-19. The intent is to reduce transmission of SARS-CoV-2 by those with documented or suspected infection by replacing CPAP therapy for sleep apnea with aerSleep® I
Sommetrics , Inc., which provides products to treat airway obstruction during sleep and in acute care settings, announced today that its quality management system has been certified to the rigorous ISO 13485:2016 standard. During the audit process required for certification, Sommetrics was also evaluated and found to be in compliance with the standards of the Medical Device Single Audit Program (MDSAP) for Canada. “This is
Sommetrics , Inc. a company providing products and services to improve sleep quality, and its partially owned affiliate, aerFree, LLC, which is dedicated to improving acute airway management, today announced the donation of their aerFree® product to leading academic centers to assist in the management of COVID-19 respiratory impairment. aerFree® is a FDA cleared, single use product intended to maintain the patency of the u
Sommetrics, a company dedicated to developing state of the art products to treat obstructive sleep apnea (OSA), today announced the completion of clinical study SOM-014
Sommetrics announced that they have been named as one of the winners of Red Herring’s 2019 Top 100 North America, recognizing the continent’s most exciting and innovative private technology companies.
Sommetrics announced it has been selected to participate in the annual Red Herring Top 100 competition in Los Angeles on May 15, 2019.
Ebb Therapeutics announces that its added Ray Huggenberger to its Board of Directors.
Sommetrics Awarded Frost & Sullivan 2018 Visionary Innovation Leadership Award for Acute Airway Management
Sommetrics announced that it has been awarded the Frost & Sullivan 2018 Visionary Innovation Leadership Award for Acute Airway Management.
Sommetrics today announced it has added industry leader David Schlotterbeck to its advisory board.
Renowned Sleep Expert Dr. Jerrold Kram to Present New Sleep Apnea Treatment by Sommetrics at SLEEP 2018
Sommetrics announced that renowned sleep expert Jerrold Kram, M.D., FCCP, FAASM, will be discussing the company’s new sleep apnea treatment, aerSleepTM, during SLEEP 2018, the 32nd Annual Meeting of the Associated Professional Sleep Societies in Baltimore, Maryland.
The company also recently engaged Key West Investments to help raise additional capital to support the development and commercialization of products and services to treat disorders of the upper airway, such as obstructive sleep apnea and snoring.
AvantSleep will distribute aerSleep in select Canadian markets, followed by a full Canadian launch in 2018.
Sommetrics Engages Key West Investments to Raise Additional Capital, Prepares for Commercialization of Sleep Apnea Therapy
Sommetrics today announced that it has engaged Key West Investments to help raise additional capital. This capital will support the company’s development and commercialization of products to treat disorders of the upper airway such as obstructive sleep apnea and chronic snoring.
Sommetrics Expands Board Of Directors And Management Team To Prepare For Canadian Launch Of New Sleep Apnea Therapy